Similar results were also observed in the neoadjuvant setting of NSCLC, in which responding patients enhanced the amount of Ki67+CD8+ T cells after chemoimmunotherapy (27), confirming that circulating cells could be considered an effective reservoir of T cells activated against the tumor. This evidence concerns the gene CD8A and neoplasm.